CareDx (CDNA) Projected to Post Quarterly Earnings on Wednesday

CareDx (NASDAQ:CDNA) is projected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect CareDx to post earnings of $0.05 per share and revenue of $84.56 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

CareDx Price Performance

Shares of CareDx stock opened at $22.29 on Monday. The business’s fifty day moving average price is $22.69 and its two-hundred day moving average price is $25.41. The company has a market capitalization of $1.20 billion, a P/E ratio of -8.26 and a beta of 1.87. CareDx has a 1-year low of $7.42 and a 1-year high of $34.84.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CDNA. HC Wainwright reiterated a “neutral” rating and set a $26.00 price target on shares of CareDx in a report on Tuesday, January 14th. BTIG Research lowered their price target on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, November 5th. StockNews.com downgraded CareDx from a “buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and lowered their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.33.

Insider Buying and Selling

In other news, Director Peter Maag sold 5,000 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the director now owns 330,024 shares of the company’s stock, valued at $8,250,600. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.90% of the stock is owned by corporate insiders.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.